Abstract
As intrathoracic organ transplantation has evolved as a routine procedure for treating endstage heart or lung disease with good early results, interest focusses nowadays on consequences of long-term immunosuppression. These are primarily impaired renal function, induction of malignancies, and chronic rejection. We are presenting our experience in 902 intrathoracic organ transplant recipients. Over the years, we have changed our immunosuppression from rather standardized to individualized treatment based on immunologic monitoring and non-invasive day-by-day rejection monitoring. Early postoperative infectious complications diminished after reducing induction therapy with ATG in compromized recipients (for example diabetics, post mechanical assist, elderly recipients). Thus use of Urodilatin helped preventing severe renal failure and allowed high levels of Cyclosporin A in the early phase after transplantation. We hope that this individualized immunosuppressive therapy will further lead to improved long-term graft survival and reduced incidence of graft vasculopathy and reduced induction of malignancies.
| Translated title of the contribution | Modern aspects in immunosuppressive therapy after intrathoracic organ replacement |
|---|---|
| Original language | German |
| Pages (from-to) | 200-204 |
| Number of pages | 5 |
| Journal | Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft |
| Volume | 7 |
| Issue number | 4 |
| State | Published - Dec 1 1995 |
Keywords
- heart transplantation
- heart-lung transplantation
- immunologic monitoring
- immunosuppression
- malignancy
ASJC Scopus subject areas
- Immunology and Allergy
- Transplantation